Researchers presented data from a study that aimed to evaluate pentraxin-3 (PTX3) as a circulating marker of inflammation in patients with suspected myocarditis.
Mitochondrial disorders have shown phenotypic and genetic heterogeneity; cytochrome c oxidase assembly protein COX11 is an assembly factor that works as a copper chaperone. Previous findings have unveiled that COX11 knockdown causes a reduction in ATP production in vitro.
Researchers from Italfarmaco SpA presented a new class of highly selective histone deacetylase 6 (HDAC6) inhibitors as potential candidates for the treatment of several pathologies, such as autoimmune disorders, neurodegenerative diseases, and cancer.
Investments in early stage biotech companies were in focus at the Hong Kong Stock Exchange’s (HKEX) Biotech Summit 2022. The virtual event on Sept. 1 saw discussions centered on this investment trend for younger biotech firms, which looks to be where capital is headed in the sector after a cooldown for listings in Chinese stock markets in the first half of 2022.
Researchers from Istituto di Ricerche Farmacologiche Mario Negri aimed to characterize lectin pathway (LP) activation after ischemic stroke in a novel humanized mouse model expressing human mannose-binding lectin.
Structure-guided design for carbazole antagonists of Toll-like receptors 7 and 8 (TLR7/8) for the potential treatment of autoimmune disorders was reported by Bristol Myers Squibb Co. TLR activation can induce proinflammatory pathway activation, which has been identified in patients with lupus.
Researchers from the University of Pittsburgh presented preclinical data for novel messenger RNA (mRNA) therapy consisting of human very long chain acyl-CoA dehydrogenase (hVLCAD) mRNA; the product is being developed as a potential treatment of VLCAD deficiency.
The Massachusetts Institute of Technology (MIT) has developed collagen mimetic peptides for PET imaging to detect idiopathic pulmonary fibrosis (IPF), with [68Ga]DOTA-CMP showing selective identification of fibrotic collagen in vivo.
There is still a percentage of patients with multiple myeloma (MM) who do not respond to initial therapy, and they are considered as refractory MM patients. There is a need for novel biomarkers of treatment response in refractory MM.
RSS
